Gabriela Calamante (ORCID 0000-0003-3968-190X) was born in Buenos Aires, Argentina. She is currently a senior researcher at INTA (level 10, grade 27) and leads the Pox and Adenovirus-Vectorized Vaccines group at the Biotechnology Institute IABiMO UEDD INTA-CONICET. She graduated from the University of Buenos Aires with a Bachelor's degree in Biological Sciences with honors (1991) and earned a PhD in Biological Sciences from the same university (1997). She has extensive experience in molecular biology, biotechnology and virology specifically in the development of recombinant vaccines. She established the poxviral vector platform (canarypox, fowlpox, and MVA) in Argentina. As a result of her work, a recombinant canarypox vector was transferred to the Argentine private sector, leading to the registration of the first recombinant vaccine developed in the country (2017). Her research group also utilizes adenoviral (AdHu5-deltaE) and plasmid vectors. The platforms implemented at INTA have supported the completion of 14 PhD theses (2007-2021), with 4 more currently in progress. Her research projects focus on developing vectorized vaccines for disease prevention within the One Health framework, particularly third-generation rabies vaccines. In recognition of her contributions, Gabriela Calamante has received several prestigious awards in Argentina, including the Innovar Award (2017), the La Nación-Banco Galicia Agricultural Excellence Award (2018), and the CiTA Award (2019).
INTA
Buenos Aires, Argentina
Inst. de Biotecnología IABIMO UEDD INTA-CONICET